Literature DB >> 27262748

Cystic fibrosis in Latin America-Improving the awareness.

Luiz Vicente Ribeiro F Silva Filho1, Claudio Castaños2, Héctor Hernán Ruíz3.   

Abstract

The burden of cystic fibrosis (CF) in Latin America is being increasingly recognized and is significant compared with other regions of the world. In this short communication, we assess the current situation in some Latin American countries and make suggestions for possible directions for future focus. We discuss the work that remains in deciphering how the various genetic, environmental and medical factors interact and influence outcomes in different ethnic groups. We also consider the need for consistency in both research and access to services across Latin America, including CF registries, neonatal screening programs, access to specialized CF healthcare practitioners, transition to adult clinics and treatment regimens. Progress in these areas is likely to build on the advances to date, and improve the lives of patients in Latin America who are affected by this debilitating and life-limiting disorder. Copyright Â
© 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Awareness; Cystic fibrosis; Diagnosis; Latin America; Management; Progress

Mesh:

Year:  2016        PMID: 27262748     DOI: 10.1016/j.jcf.2016.05.007

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  9 in total

Review 1.  Pseudomonas aeruginosa and Klebsiella pneumoniae Adaptation to Innate Immune Clearance Mechanisms in the Lung.

Authors:  Sebastian A Riquelme; Danielle Ahn; Alice Prince
Journal:  J Innate Immun       Date:  2018-04-04       Impact factor: 7.349

2.  Characterization of Ancestral Origin of Cystic Fibrosis of Patients with New Reported Mutations in CFTR.

Authors:  César Paz-Y-Miño; Ana Karina Zambrano; Juan Carlos Ruiz-Cabezas; Isaac Armendáriz-Castillo; Jennyfer M García-Cárdenas; Santiago Guerrero; Andrés López-Cortés; Andy Pérez-Villa; Patricia Guevara-Ramírez; Verónica Yumiceba; Paola E Leone
Journal:  Biomed Res Int       Date:  2020-05-29       Impact factor: 3.411

3.  Standardized clinical criteria and sweat test combined as a tool to diagnose Cystic Fibrosis.

Authors:  Fabricio González-Andrade
Journal:  Heliyon       Date:  2018-12-17

4.  Next-generation sequencing for identifying a novel/de novo pathogenic variant in a Mexican patient with cystic fibrosis: a case report.

Authors:  Angélica Martínez-Hernández; Julieta Larrosa; Francisco Barajas-Olmos; Humberto García-Ortíz; Elvia C Mendoza-Caamal; Cecilia Contreras-Cubas; Elaheh Mirzaeicheshmeh; José Luis Lezana; Lorena Orozco
Journal:  BMC Med Genomics       Date:  2019-05-22       Impact factor: 3.063

5.  Cystic fibrosis revisited.

Authors:  H Kulkarni; S Kansra; S Karande
Journal:  J Postgrad Med       Date:  2019 Oct-Dec       Impact factor: 1.476

Review 6.  Newborn Screening for CF across the Globe-Where Is It Worthwhile?

Authors:  Virginie Scotet; Hector Gutierrez; Philip M Farrell
Journal:  Int J Neonatal Screen       Date:  2020-03-04

7.  Lower airway microbiota and decreasing lung function in young Brazilian cystic fibrosis patients with pulmonary Staphylococcus and Pseudomonas infection.

Authors:  Paulo Kussek; Dany Mesa; Thaís Muniz Vasconcelos; Luiza Souza Rodrigues; Damaris Krul; Humberto Ibanez; Helisson Faoro; Jussara Kasuko Palmeiro; Libera Maria Dalla Costa
Journal:  PLoS One       Date:  2022-08-25       Impact factor: 3.752

8.  Clinical, genetic and microbiological characterization of pediatric patients with cystic fibrosis in a public Hospital in Ecuador.

Authors:  Yazmina Lascano-Vaca; Esteban Ortiz-Prado; Lenin Gomez-Barreno; Katherine Simbaña-Rivera; Eduardo Vasconez; Alexander Lister; María Emilia Arteaga-Espinosa; Geovanny F Perez
Journal:  BMC Pediatr       Date:  2020-03-06       Impact factor: 2.125

9.  Challenges in providing residual risks in carrier testing.

Authors:  Robert Luke Nussbaum; Robert Nathan Slotnick; Neil J Risch
Journal:  Prenat Diagn       Date:  2021-06-13       Impact factor: 3.050

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.